Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies,
Combinations, and Other...
Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies,
Combinations, and Other...
Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies,
Combinations, and Other...
Nächste SlideShare
Wird geladen in …5
×

Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

57 Aufrufe

Veröffentlicht am

Suresh S. Ramalingam, MD, FACP, FASCO, prepared a useful Practice Aids with resources for patients with lung cancer for this CME/MOC activity titled, "Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2UA1d4f. CME/MOC credit will be available until June 14, 2021.

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

  • Gehören Sie zu den Ersten, denen das gefällt!

Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

  1. 1. Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer,” at PeerView.com/WCZ40 Lung Cancer Patient Education and Engagement in Care Decisions: Resource Compendium1-7 PRACTICE AID Considering patient preferences, goals, and values is of increasing importance in lung cancer because the complexity of the treatment landscape is growing, resulting in more options and the need for more individualized approaches to treatment selection, and planning that, in addition to considering the evidence and best practice recommendations, should take into account the needs and preferences of patients with lung cancer and their caregivers Shared decision-making (SDM)—a process of two-way communication during which clinicians and patients work together to make treatment and other care-related decisions—has been found to provide many important benefits to patients, clinicians, healthcare systems, and society as a whole Providers share key disease state and treatment-related information Patients communicate values, risk attitudes, and treatment goals High quality information and resources are essential in supporting shared decision-making in lung cancer! go2foundation.org Transforming survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer
  2. 2. Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer,” at PeerView.com/WCZ40 Lung Cancer Patient Education and Engagement in Care Decisions: Resource Compendium1-7 PRACTICE AID Patient-focused, accessible, free programs are the foundation of GO2 resources that educate, support, empower, and provide hope to all those living with lung cancer Patient & Support Services • HelpLine: personalized navigation • Online support communities • Phone Buddies: peer-to-peer support • LungMATCH: treatment and trial navigation • Lung Cancer Living Room™ • “Bringing Hope Home” • Lung Cancer Support Group Network • Educational materials: patient-/caregiver-friendly handbooks and brochures ö Understanding Your Diagnosis ö Understanding Non–Small Cell Lung Cancer ö Understanding Small Cell Lung Cancer ö Understanding Lung Cancer Biopsies ö Biomarker Testing ö Understanding Your Lung Cancer Pathology Report ö Immunotherapy for Lung Cancer ö Understanding Lung Cancer Clinical Trials ö Playing a Critical Role: Lung Cancer Caregiver
  3. 3. Access the activity, “Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer,” at PeerView.com/WCZ40 Lung Cancer Patient Education and Engagement in Care Decisions: Resource Compendium1-7 PRACTICE AID 1. National Quality Partners Playbook Playbook™: Shared Decision Making in Healthcare. 2018 National Quality Forum. 2. Preference Sensitive Care From the Patient Protection and Affordable Care Act (2010). 3. Center for the Evaluative Clinical Sciences. Preference-Sensitive Care. Lebanon, NH: Dartmouth Atlas Project; 2007. 4. Alston C et al. IOM 2014. https://nam.edu/wp-content/uploads/2015/06/ SDMforBestCare2.pdf. 5. Sepucha KR et al. Med Decis Making. 2010;30(suppl 6):775-845. 6. Frosch DL et al. Health Aff (Millwood). 2012;3:1030-1038. 7. Cramm JM, Nieboer AP. BMJ Open. 2014;4:e005914. Annual National Advocacy Summit, awareness raising, and events bring people together to improve lung cancer at all levels Building Community & Making an Impact • Ambassador Program • Shine A Light Awareness Events • Patient Advocacy Summit in D.C. • National Event Series/Grassroots Events (walks and runs) Lung Cancer Registry • Patient and caregiver reported data • ~2,000 participants • Diagnosis, treatment, and quality of life data • Quarterly, IRB-approved longitudinal surveys • Partnership with the American Lung Association and International Association for the Study of Lung Cancer (IASLC) National Ambassador Council www.lungcancerregistry.org

×